Efficacy and Safety of IBI310 Combined With Sintilimab in Patients With Advanced Hepatocellular Carcinoma
About the study
An open-label, single-arm, Ib study of the efficacy and safety of IBI310 combined with sintilimab in patients with advanced hepatocellular carcinoma
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
inclusion criteria:
- Locally advanced or metastatic hepatocellular carcinoma, confirmed by histology/cytology.
- Disease progression after surgery and / or local treatment.
- Previous standard systemic treatments for advanced hepatocellular carcinoma have failed or developed intolerable toxicity.
EXCLUSION CRITERIA
exclusion criteria:
- Histology contains fibrous lamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma and other components.
- Have a history of hepatic encephalopathy, or have a history of liver transplantation.
- Diffuse liver cancer.
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Advanced Hepatocellular Carcinoma
Age (in years)
18 - 75
Phase
Phase 1
Participants needed
97
Est. Completion Date
Apr 30, 2023
Treatment type
Interventional
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
ClinicalTrials.gov identifier
NCT04401813
Study number
CIBI310C101
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?